Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
|
Xlife Sciences AG / Key word(s): Market Report Zurich, 5th of May 2025: Xlife Sciences AG («Xlife Sciences»; SIX: XLS) today published its 2024 Valuation Report, evaluating the company’s project portfolio as of December 31, 2024. The independent consulting firm CYLAD Consulting conducted the assessment, which covers 16 project companies within Xlife Sciences’ total portfolio1. CYLAD Consulting based its assessment on financial forecasts and strategic plans, supplemented by site visits and discussions with the management of the respective project company. The evaluation was performed using the risk-adjusted net present value (rNPV) method, widely applied in the life sciences industry. Key parameters for the valuation included cost of capital and development risks specific to the project companies.
Oliver R. Baumann, CEO of Xlife Sciences, commented: «The 2024 Valuation Report again confirms the strong potential of our portfolio. Our model of accelerating innovative projects from top academic institutions toward commercialization continues to create substantial value for our shareholders. We remain focused on strategic project development and selective international expansion, including the validation of our business model by transaction/partial exits as with the most recent VERAXA Biotech AG announcement.» Following the intended capital market transaction of FUSE-AI GmbH and the associated offer from Pineapple Power Corporation PLC to acquire the company at an expected valuation of EUR 80-90 million and thus take it public (LSE, UK), additional incoming offers and opportunities were carefully reviewed. In close coordination with Xlife Sciences AG and other strategic partners, the company has decided to align a potential listing with the current valuation report (EUR 100-115 million) and, in consultation with strategic co-investors, to target the more attractive U.S. market. This approach aims to achieve broader market entry, faster scaling, and access to the necessary growth capital. The full 2024 Valuation Report can be downloaded at: https://www.xlifesciences.ch/en/news-and-key-figures (Section «Financial Reports») 1 The eight project companies Firstgene Therapeutics GmbH, XRNA Biotech GmbH, xprot GmbH, novaxomx GmbH, Novum Technologie GmbH, Xsight Optics GmbH, QUADIRA BIOSCIENCES AG and 4D Lifetec AG were not evaluated.
Financial calendar
Contact Xlife Sciences AG, End of Inside Information |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2129444 |
| End of Announcement | EQS News Service |
|
|
2129444 05-May-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.